Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Core Insights - Axsome Therapeutics is actively participating in Mental Illness Awareness Week (MIAW) to promote mental health awareness and community support [1][2] - The theme for this year's MIAW is "Building Community: Supporting Mental Well-being Together," emphasizing the importance of grassroots advocacy and local action [1][2] - Axsome is committed to supporting individuals with mental health conditions and collaborates with organizations like NAMI to provide resources and reduce stigma [3][4] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraines [4] - The company aims to address critical gaps in care and develop innovative products that improve patient outcomes, impacting over 150 million people in the U.S. [4] - Axsome partners with national and global advocacy organizations to strengthen communities and provide support for those affected by mental health challenges [3][4] Mental Health Statistics - Over 1 in 5 adults in the U.S. experience mental illness each year, and more than 1 in 7 youth aged 6-17 also face mental health conditions annually [3] - Nearly 90% of individuals living with depression report difficulties in work, home, or social activities due to their symptoms, highlighting the significant impact of depression [3]